From the1International Diabetes Center and University of Minnesota, Minneapolis, Minnesota; the2Section of Diabetes, Oregon Health & Science University, Portland, Oregon; the3Dallas Diabetes and Endocrine Center, Dallas, Texas; and4Amylin Pharmaceuticals, San Diego, California. Address correspondence and reprint requests to Alain D. Baron, MD, Senior Vice President, Research, Amylin Pharmaceuticals, 9360 Towne Centre Dr., Suite 110, San Diego, CA 92121. E-mail: abaron@amylin. com. Received for publication 27 September 2004 and accepted in revised form 31 January 2005.D.M.K. has served on an advisory panel for Amylin/Lilly; has received honoraria from Eli Lilly, Amylin,